DaVita (DVA) to Release Earnings on Tuesday

DaVita (NYSE:DVA) is anticipated to issue its Q1 2026 results after the market closes on Tuesday, May 5th. Analysts expect the company to announce earnings of $2.33 per share and revenue of $3.3564 billion for the quarter. DaVita has set its FY 2026 guidance at 13.600-15.00 EPS. Parties may review the information on the company’s upcoming Q1 2026 earning report for the latest details on the call scheduled for Tuesday, May 5, 2026 at 5:00 PM ET.

DaVita (NYSE:DVA) last released its earnings results on Monday, February 2nd. The company reported $3.40 earnings per share for the quarter, topping the consensus estimate of $3.24 by $0.16. The business had revenue of $3.62 billion for the quarter, compared to the consensus estimate of $3.51 billion. DaVita had a net margin of 5.47% and a negative return on equity of 413.18%. The firm’s quarterly revenue was up 9.9% compared to the same quarter last year. During the same period last year, the firm posted $2.24 earnings per share. On average, analysts expect DaVita to post $14 EPS for the current fiscal year and $17 EPS for the next fiscal year.

DaVita Stock Up 0.5%

Shares of DaVita stock traded up $0.77 during trading on Tuesday, hitting $150.82. The stock had a trading volume of 135,258 shares, compared to its average volume of 979,368. The stock has a 50 day simple moving average of $150.94 and a 200 day simple moving average of $130.93. The company has a market capitalization of $10.07 billion, a PE ratio of 15.22, a P/E/G ratio of 0.53 and a beta of 0.92. DaVita has a 1 year low of $101.00 and a 1 year high of $159.42.

Analyst Upgrades and Downgrades

Several equities research analysts recently issued reports on DVA shares. TD Cowen reissued a “hold” rating on shares of DaVita in a research note on Tuesday, February 3rd. Weiss Ratings reissued a “hold (c)” rating on shares of DaVita in a research note on Monday, December 29th. Wall Street Zen raised DaVita from a “hold” rating to a “buy” rating in a research note on Saturday, February 21st. UBS Group increased their price objective on DaVita from $186.00 to $190.00 and gave the stock a “buy” rating in a research note on Wednesday, February 4th. Finally, Truist Financial set a $158.00 price objective on DaVita in a research note on Thursday, February 5th. One investment analyst has rated the stock with a Buy rating, five have assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus target price of $155.80.

Hedge Funds Weigh In On DaVita

Several hedge funds and other institutional investors have recently added to or reduced their stakes in DVA. Gen Wealth Partners Inc boosted its stake in shares of DaVita by 10.0% in the 4th quarter. Gen Wealth Partners Inc now owns 880 shares of the company’s stock valued at $100,000 after purchasing an additional 80 shares during the last quarter. NewEdge Advisors LLC increased its holdings in DaVita by 20.8% in the first quarter. NewEdge Advisors LLC now owns 511 shares of the company’s stock valued at $78,000 after purchasing an additional 88 shares during the last quarter. Orion Porfolio Solutions LLC increased its holdings in DaVita by 4.4% in the fourth quarter. Orion Porfolio Solutions LLC now owns 2,360 shares of the company’s stock valued at $268,000 after purchasing an additional 99 shares during the last quarter. Bank of Nova Scotia increased its holdings in DaVita by 2.5% in the third quarter. Bank of Nova Scotia now owns 4,933 shares of the company’s stock valued at $655,000 after purchasing an additional 120 shares during the last quarter. Finally, Daiwa Securities Group Inc. increased its holdings in DaVita by 2.2% in the second quarter. Daiwa Securities Group Inc. now owns 6,502 shares of the company’s stock valued at $926,000 after purchasing an additional 138 shares during the last quarter. Institutional investors own 90.12% of the company’s stock.

About DaVita

DaVita Inc (NYSE: DVA) is a leading provider of kidney care services, specializing in the management and operation of outpatient dialysis centers for patients with chronic kidney failure and end-stage renal disease. Headquartered in Denver, Colorado, the company offers a comprehensive suite of treatment modalities, including in-center hemodialysis, peritoneal dialysis, and home dialysis therapies. In addition to its core dialysis services, DaVita provides patient education, nutritional counseling, vascular access management and related laboratory services to support kidney health and overall patient well-being.

Since its formation in the mid-1990s through a clinical management services spin-off, DaVita has expanded both organically and through strategic partnerships and acquisitions.